Seattle Genetics, Inc. (NASDAQ:SGEN) recovered 27.92% of its value since hitting low of $47.75. The recent move of -4.49% drop pushed the stock to close at $61.08 when trading ended on 12/04/2018. At recent session, the prices were hovering between $61.02 and $64.39. This company shares are 31.57% off its target price of $80.36 and the current market capitalization stands at $9.9B. The recent change has given its price a -7.52% deficit over SMA 50 and -27.6% deficit over its 52-week high. The stock witnessed 8.2% gains, -20.63% declines and -6.55% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGEN’s volatility during a week at 4.14% and during a month it has been found around 4.61%.Seattle Genetics, Inc. (SGEN) Top Holders
Institutional investors currently hold around $10.5 billion or 0% in SGEN stock. Look at its top three institutional owners. Baker Bros. Advisors Lp owns $3.26 billion in Seattle Genetics, Inc., which represents roughly 32.97% of the company’s market cap and approximately 31.1% of the institutional ownership. Similar statistics are true for the second largest owner, Primecap Management Co/Ca/, which owns 14,456,100 shares of the stock are valued at $924.47 million. The third largest holder is Baillie Gifford & Co, which currently holds $862.39 million worth of this stock and that ownership represents nearly 8.71% of its market capitalization.
At the end of September reporting period, 166 institutional holders increased their position in Seattle Genetics, Inc. (NASDAQ:SGEN) by some 7,958,105 shares, 124 decreased positions by 9,781,435 and 71 held positions by 146,399,120. That puts total institutional holdings at 164,138,660 shares, according to SEC filings. The stock grabbed 67 new institutional investments totaling 882,143 shares while 25 institutional investors sold out their entire positions totaling 2,376,165 shares.Seattle Genetics, Inc. (NASDAQ:SGEN) Insider Trades
Multiple company employees have indulged in significant insider trading. Seattle Genetics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Technical Officer Himes Vaughn B has sold 5,000 shares of Seattle Genetics, Inc. (SGEN) in trading session dated Nov. 30, 2018. These shares are worth $310,700 and were traded at $62.14 each. The SEC filing shows that Cline Darren S performed a sale of 7,000 shares. The EVP, Commercial disposed these shares by way of transaction on Nov. 29, 2018. The company’s shares were given away at $62.88 per share worth to an income of some $440,160 on account of Cline Darren S.
EVP, Commercial, Cline Darren S, sold 4,167 common shares of Seattle Genetics, Inc. (SGEN) in the open market. In a transaction dated Nov. 21, 2018, the shares were put up for sale at an average price of $56.68, raking in a sum of $236,186. After this sale, 79,556 common shares of SGEN are directly owned by the insider, with total stake valued at $4,859,281.
In the transaction dated Nov. 08, 2018, the great number of shares disposed came courtesy the President and CEO; Siegall Clay B disposed a total of 20,148 shares at an average price of $61.54, amounting to approximately $1,239,908. The insider now directly owns 732,613 shares worth $44,748,002.
Several analysts have released their opinion on Seattle Genetics, Inc. (NASDAQ:SGEN), with 3 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 5 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.23 average brokerage recommendation.